statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

For the last three days, A.I.dvisor has detected that ALT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Altimmune (ALT, $10.25) Aroon Indicator entered a Downtrend on April 01, 2024.

This is a Bullish indicator signaling ALT's price could rise from here. Traders may explore going long the stock or buying call options...

Altimmune (ALT, $10.25) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 12,510,000...

Short Interest in Altimmune, Inc. (NASDAQ:ALT) Grows By 15.7%

B. Riley reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a report issued on Thursday, Benzinga reports. The firm currently has a $20.00 price objective on the stock...

Altimmune (NASDAQ:ALT) Earns Buy Rating from B. Riley

Altimmune (NASDAQ:ALT - Get Free Report)s stock had its "buy" rating reaffirmed by B. Riley in a research note issued on Thursday, Benzinga reports. They presently have a $20.00 price...

Altimmune (NASDAQ:ALT) Stock Rating Reaffirmed by B. Riley

A new kind of injectable GLP-1 medication may help patients preserve more muscle mass than Ozempic and Mounjaro. CR/Getty ImagesA new GLP-1 drug, pemvidutide, helped patients lose fat while...

A new Ozempic rival helps patients lose fat, but keep their muscle &mdash; the holy grail for a weight-loss drug

Investors might want to bet on Altimmune, Inc. (ALT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of...

Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade

Altimmune, Inc. (NASDAQ:ALT  Get Free Report)s stock price shot up 5.3% during trading on Thursday . The company traded as high as $9.38 and last traded at $9.36. 660,352 shares changed...

Altimmune (NASDAQ:ALT) Shares Up 5.3%

Q4 2023 Altimmune Inc Earnings Call Transcript

Key Insights Institutions' substantial holdings in Altimmune implies that they have significant influence over the...

Altimmune, Inc. (NASDAQ:ALT) is definitely on the radar of institutional investors who own 44% of the company

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Volume	2.25M
52-Wk High	$14.84
52-Wk Low	$2.09

ALT Altimmune Inc

About

Feed

News

Sentiment

Earnings

Fundamentals